viewSilence Therapeutics PLC

Silence Therapeutics gets one over on Alnylam in ongoing patent battle

The US Patent Trial and Appeal Board found that Alnylam didn’t have enough evidence to prove a patent recently awarded to Silence should be invalidated

A trial between the two companies is expected to begin in the UK in December

Silence Therapeutics PLC (LON:SLN) has been given another boost in its ongoing patent battle with US biotech giant Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY).

Alnylam had challenged the validity of five patents recently issued to Silence, and the first of those petitions has been thrown out by US authorities.

READ: The Silence-Alnylam wrangle takes another turn

The US Patent Trial and Appeal Board found that Alnylam, valued at more than US$8bn, had failed to show enough evidence that the claims were invalid.

Silence said the PTAB’s decision not to review the issue of the patent “provides yet another vindication” of the strength of its intellectual property.

Decisions on the remaining patents are due over the next several months.

“We are very pleased with this favourable outcome in US patent office proceedings initiated by Alnylam,” said chief executive David Horn Solomon.

“We are hopeful that the remaining proceedings will result in similar outcomes and that Silence's patent position will be fully vindicated.”

IN-DEPTH: Silence to kick off first clinical trial next year

Earlier this week, Silence told investors that European authorities are close to granting it another patent further protecting its gene silencing technology.

Silence has gone to war with Alnylam and others over the past year or so, claiming that they have been using technology covered by its patents in drugs that silence genes and may be fundamental in the war against cancer.

A court hearing in the UK between Silence and Alnylam – the company behind patisiran, the drug approved by the US Food and Drug Administration earlier this year – is expected to start in the UK in December.

Silence shares were down 1.2% to 120p.

Quick facts: Silence Therapeutics PLC

Price: 457 GBX

Market: AIM
Market Cap: £378.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...



Market Report: FTSE 100 retreats as UK employment tumbles

Headlines from the Proactive UK newsroom. The FTSE100 was on the back foot as the new job numbers highlighted how business is suffering due to the pandemic. The blue chip-index shed 60 to 6,232. People on UK payrolls fell by 649,000 between March and June, according to the government....

2 weeks, 5 days ago

2 min read